What is LIGAND PHARMS GENERAL CVR's earnings per share (EPS)?

LIGAND PHARMS GENERAL CVR (LGNYZ) reported diluted earnings per share of $6.13 for fiscal year 2025. This represents a 2886.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

LIGAND PHARMS GENERAL CVR (LGNYZ) Financials

LGNYZ

Trailing 12 months to June 30, 2026

Revenue $290.5M +54.9% YoY

Net Income $197.2M +360.0% YoY

EPS (Diluted) $9.41 +332.9% YoY

Free Cash Flow $131.4M +145.1% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 7, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LGNYZ SEC filings page.

LIGAND PHARMS GENERAL CVR (LGNYZ) reported $290.5M in revenue over the twelve months to Jun 30, 2026, up 54.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LGNYZ FY2025 2026-08-29

Operating recovery coexists with a cash-conversion gap and balance-sheet expansion funded largely through financing.

In FY2025, net margin of 46.4% far exceeded operating margin of 15.3%, indicating the bottom-line result was not explained by core operating profit alone. Operating cash flow of $49.4M was less than half net income of $124.5M, so reported profit carried a pronounced cash-conversion gap.

The shift from a -13.5% operating margin in FY2024 to 15.3% in FY2025 shows the rebound reached the operating engine rather than appearing only below the operating line. Yet SG&A reached $92.4M and R&D $81.2M, meaning recovery occurred alongside a much larger expense base, not simple cost reduction.

FY2025 investing cash flow of -$377.3M against capex of $452K indicates the large deployment was mostly something other than routine capital spending. Financing cash flow of $428.2M nearly offset it while total assets expanded sharply, making funding flows central to interpreting the year's balance-sheet growth.

Financial Health Signals

Financial health score not available

LIGAND PHARMS GENERAL CVR does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

4/7

LIGAND PHARMS GENERAL CVR passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.40x

For every $1 of reported earnings, LIGAND PHARMS GENERAL CVR generates $0.40 in operating cash flow ($49.4M OCF vs $124.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe

8.70x

LIGAND PHARMS GENERAL CVR earns $8.70 in operating income for every $1 of interest expense ($41.0M vs $4.7M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$63.7M

YoY+33.7%

QoQ+23.1%

5Y CAGR-4.2%

10Y CAGR+12.6%

LIGAND PHARMS GENERAL CVR generated $63.7M in revenue in Q2 2026. This represents an increase of 33.7% from the same quarter a year earlier. Against the prior quarter it is up 23.1%.

EBITDA

$16.8M

YoY-0.9%

QoQ-34.3%

LIGAND PHARMS GENERAL CVR's EBITDA was $16.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 0.9% from the same quarter a year earlier. Against the prior quarter it is down 34.3%.

Net Income

$48.5M

YoY+900.8%

QoQ+463.5%

5Y CAGR+9.6%

LIGAND PHARMS GENERAL CVR reported $48.5M in net income in Q2 2026. This represents an increase of 900.8% from the same quarter a year earlier. Against the prior quarter it is up 463.5%.

EPS (Diluted)

$2.22

YoY+825.0%

QoQ+431.3%

5Y CAGR+4.4%

LIGAND PHARMS GENERAL CVR earned $2.22 per diluted share (EPS) in Q2 2026. This represents an increase of 825.0% from the same quarter a year earlier. Against the prior quarter it is up 431.3%.

Cash & Balance Sheet

Free Cash Flow

$24.0M

YoY+53.9%

QoQ-50.5%

5Y CAGR+4.8%

LIGAND PHARMS GENERAL CVR generated $24.0M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 53.9% from the same quarter a year earlier. Against the prior quarter it is down 50.5%.

Cash & Debt

$1.0B

YoY+1387.7%

QoQ+774.8%

5Y CAGR+115.1%

10Y CAGR+32.3%

LIGAND PHARMS GENERAL CVR held $1.0B in cash against $1.1B in long-term debt as of Q2 2026.

Shares Outstanding

20M

YoY+1.7%

QoQ-0.5%

5Y CAGR+3.6%

10Y CAGR-0.4%

LIGAND PHARMS GENERAL CVR had 20M shares outstanding in Q2 2026. This represents an increase of 1.7% from the same quarter a year earlier. Against the prior quarter it is down 0.5%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Operating Margin

13.5%

YoY-4.2pp

QoQ-20.1pp

LIGAND PHARMS GENERAL CVR's operating margin was 13.5% in Q2 2026, reflecting core business profitability. This is down 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 20.1 percentage points.

Net Margin

76.2%

YoY+66.0pp

QoQ+102.0pp

5Y change+37.2pp

10Y change+107.8pp

LIGAND PHARMS GENERAL CVR's net profit margin was 76.2% in Q2 2026, showing the share of revenue converted to profit. This is up 66.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 102.0 percentage points.

Return on Equity

5.0%

YoY+4.4pp

QoQ+6.3pp

5Y change+1.1pp

10Y change+6.9pp

LIGAND PHARMS GENERAL CVR's ROE was 5.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 4.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$14.7M

YoY+123.4%

QoQ+582.9%

5Y CAGR+14.4%

LIGAND PHARMS GENERAL CVR invested $14.7M in research and development in Q2 2026. This represents an increase of 123.4% from the same quarter a year earlier. Against the prior quarter it is up 582.9%.

Capital Expenditures

$26K

YoY-87.9%

QoQ-88.6%

5Y CAGR-54.9%

LIGAND PHARMS GENERAL CVR invested $26K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 87.9% from the same quarter a year earlier. Against the prior quarter it is down 88.6%.

Share Buybacks

Not reported for Q2 2026.

LGNYZ Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LGNYZ quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$290.5M	$268.1M+60.4%	$167.1M+27.3%	$131.3M-33.1%	$196.2M-18.8%	$241.5M+47.7%	$163.6M+36.0%	$120.3M-52.2%	$251.5M+78.2%	$141.1M+29.5%	$109.0M+51.5%	$71.9M+11.4%	$64.5M+31.8%	$49.0M+56.0%	$31.4M+4.5%	$30.0M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$6.3M+18.1%	$5.4M-3.7%	$5.6M-4.1%	$5.8M-36.4%	$9.1M+59.4%	$5.7M+59.2%	$3.6M-26.6%	$4.9M
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$245.1M+80.6%	$135.7M+31.3%	$103.4M+56.4%	$66.1M+19.3%	$55.4M+28.1%	$43.2M+55.6%	$27.8M+10.6%	$25.1M
R&D Expenses	$41.3M	$81.2M+278.9%	$21.4M-12.7%	$24.5M-32.0%	$36.1M+12.4%	$32.1M-20.7%	$40.5M-27.6%	$55.9M+100.7%	$27.9M+3.6%	$26.9M+26.7%	$21.2M+92.8%	$11.0M+12.9%	$9.7M+5.1%	$9.3M-14.1%	$10.8M+4.8%	$10.3M
SG&A Expenses	$103.4M	$92.4M+17.5%	$78.7M+49.0%	$52.8M-24.7%	$70.1M+49.7%	$46.8M-22.0%	$60.0M+43.3%	$41.9M+11.0%	$37.7M+31.7%	$28.7M+3.6%	$27.7M+8.9%	$25.4M+12.5%	$22.6M+25.5%	$18.0M+14.0%	$15.8M+8.2%	$14.6M
Operating Income	$94.7M	$41.0M+281.4%	-$22.6M-289.3%	$11.9M+293.2%	$3.0M-97.1%	$103.9M+176.9%	$37.5M-95.4%	$807.1M+392.9%	$163.7M+140.5%	$68.1M+55.1%	$43.9M+60.6%	$27.3M+39.2%	$19.6M+31.3%	$14.9M+7642.5%	$193K+122.0%	-$878K
EBITDA	N/A	$74.8M+491.9%	$12.6M-73.9%	$48.5M-11.2%	$54.6M-64.8%	$154.9M+145.2%	$63.2M-92.3%	$825.4M+367.6%	$176.5M+123.3%	$79.0M+43.2%	$55.2M+84.2%	$30.0M+34.4%	$22.3M+26.6%	$17.6M+502.9%	$2.9M+52.7%	$1.9M
Interest Expense	$6.2M	$4.7M+55.3%	$3.0M+363.0%	$656K-63.5%	$1.8M-90.8%	$19.6M-28.4%	$27.4M-23.3%	$35.7M-26.0%	$48.3M+258.7%	$13.5M+4.8%	$12.8M+208.8%	-$11.8M-342.8%	$4.9M+134.0%	$2.1M-29.0%	$2.9M+16.6%	$2.5M
Income Tax	$40.7M	$34.5M+426.8%	$6.5M-33.4%	$9.8M-76.1%	$41.2M+1094.0%	-$4.1M+21.8%	-$5.3M-103.2%	$167.3M+457.6%	$30.0M-32.8%	$44.7M+332.6%	$10.3M+105.4%	-$192.1M-46957.3%	$410K+9.6%	$374K+131.4%	-$1.2M+91.0%	-$13.3M
Net Income	$197.2M	$124.5M+3186.6%	-$4.0M-107.7%	$52.2M+256.3%	-$33.4M-158.4%	$57.1M+2014.2%	-$3.0M-100.5%	$629.3M+339.1%	$143.3M+1041.5%	$12.6M+867.5%	-$1.6M-100.7%	$229.8M+1811.4%	$12.0M+5.3%	$11.4M+2267.0%	-$527K-105.4%	$9.7M
EPS (Basic)	N/A	$6.44+3027.3%	-$0.22-107.3%	$3.02+252.5%	-$1.98-157.6%	$3.44+2011.1%	-$0.18-100.5%	$33.13+389.4%	$6.77+1028.3%	$0.60+850.0%	-$0.08-100.7%	$11.61+1867.8%	$0.59+5.4%	$0.56+1966.7%	-$0.03-106.1%	$0.49
EPS (Diluted)	$9.41	$6.13+2886.4%	-$0.22-107.5%	$2.94+248.5%	-$1.98-159.8%	$3.31+1938.9%	-$0.18-100.6%	$31.85+434.4%	$5.96+1024.5%	$0.53+762.5%	-$0.08-100.7%	$10.83+1833.9%	$0.56+1.8%	$0.55+1933.3%	-$0.03-106.1%	$0.49
Diluted Shares (Avg)	N/A	20M+11.0%	18M+3.0%	18M+5.3%	17M-2.2%	17M+2.5%	17M-14.8%	20M-17.9%	24M+2.5%	23M+12.7%	21M-1.9%	21M-1.0%	21M+3.3%	21M+4.5%	20M+0.7%	20M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$63.7M+33.7%	$51.7M+14.1%	$59.7M+39.4%	$115.5M+122.8%	$47.6M+14.7%	$45.3M+46.3%	$42.8M+52.4%	$51.8M+57.6%
R&D Expenses	$14.7M+123.4%	$2.1M-95.7%	$3.5M-20.7%	$21.0M+270.4%	$6.6M+22.7%	$50.1M+738.8%	$4.4M-19.4%	$5.7M+2.6%
SG&A Expenses	$29.1M+44.4%	$20.8M+10.8%	$25.0M-2.3%	$28.4M+16.2%	$20.2M+14.5%	$18.8M+71.7%	$25.6M+60.1%	$24.5M+67.0%
Operating Income	$8.6M+1.7%	$17.4M+148.0%	$13.8M+243.6%	$54.9M+1647.7%	$8.4M+144.2%	-$36.2M-1312.0%	-$9.6M-187.0%	$3.1M+2.1%
EBITDA	$16.8M-0.9%	$25.6M+193.2%	$22.1M+2283.9%	$63.2M+420.7%	$17.0M+265.6%	-$27.4M-333.5%	-$1.0M-118.2%	$12.1M+3.8%
Interest Expense	$1.7M+51.6%	$1.7M+101.5%	$1.8M+101.2%	$910K+22.8%	$1.2M-9.1%	$867K+514.9%	$887K+577.1%	$741K+74000.0%
Income Tax	$15.8M+147.7%	-$10.9M-41.2%	$12.0M+247.9%	$23.9M+2764.8%	$6.4M+147.3%	-$7.7M-128.3%	-$8.1M-643.5%	$833K+144.5%
Net Income	$48.5M+900.8%	-$13.3M+68.6%	$44.8M+244.1%	$117.3M+1735.2%	$4.8M+109.3%	-$42.5M-149.3%	-$31.1M-270.9%	-$7.2M+30.2%
EPS (Basic)	$2.42+868.0%	-$0.67+69.7%	$2.33+235.5%	$5.99+1635.9%	$0.25+108.7%	-$2.21-145.5%	-$1.72-263.8%	-$0.39+33.9%
EPS (Diluted)	$2.22+825.0%	-$0.67+69.7%	$2.18+229.8%	$5.68+1556.4%	$0.24+108.3%	-$2.21-146.5%	-$1.68-263.1%	-$0.39+33.9%
Diluted Shares (Avg)	22M+9.6%	20M+3.6%	N/A	21M+12.0%	20M+10.5%	19M+5.9%	N/A	18M+6.0%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

LGNYZ Balance Sheet

LGNYZ quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.6B+65.7%	$941.8M+19.6%	$787.2M+3.2%	$762.7M-41.2%	$1.3B-4.7%	$1.4B-8.9%	$1.5B+18.6%	$1.3B+87.9%	$671.0M+11.5%	$601.6M+19.6%	$503.1M+95.0%	$258.0M+146.4%	$104.7M+0.4%	$104.3M-13.5%	$120.6M
Current Assets	$832.3M+151.0%	$331.6M+39.6%	$237.4M-9.9%	$263.6M-43.3%	$464.8M-7.2%	$500.6M-55.5%	$1.1B+29.1%	$870.5M+267.3%	$237.0M+45.4%	$163.1M-24.1%	$214.7M+16.0%	$185.2M+644.2%	$24.9M+4.4%	$23.8M-26.1%	$32.2M
Cash & Equivalents	$174.9M+141.9%	$72.3M+215.0%	$23.0M-49.0%	$45.0M+130.5%	$19.5M-59.0%	$47.6M-33.4%	$71.5M-38.9%	$117.2M+468.2%	$20.6M+10.0%	$18.8M-80.8%	$97.4M-39.2%	$160.2M+1276.4%	$11.6M-6.0%	$12.4M+75.8%	$7.0M
Short-Term Investments	$558.6M+203.8%	$183.9M+24.8%	$147.4M-11.7%	$166.9M-48.1%	$321.6M-11.5%	$363.6M-63.6%	$998.3M+66.1%	$601.2M+232.1%	$181.0M+48.0%	$122.3M+19.0%	$102.8M+1341.1%	$7.1M+64.4%	$4.3M	$0-100.0%	$10.0M
Inventory	$9.1M-35.3%	$14.1M-41.1%	$24.0M+80.3%	$13.3M-51.4%	$27.3M+3.2%	$26.5M+263.0%	$7.3M+2.4%	$7.1M+62.9%	$4.4M+127.4%	$1.9M+17.8%	$1.6M+507.1%	$269K-80.7%	$1.4M-18.0%	$1.7M+30.4%	$1.3M
Accounts Receivable	$59.6M+55.3%	$38.4M+16.6%	$32.9M+8.2%	$30.4M-64.4%	$85.5M+50.3%	$56.8M+87.1%	$30.4M-45.6%	$55.9M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$101.5M-3.5%	$105.3M+1.8%	$103.4M	$0-100.0%	$105.7M-44.3%	$189.7M+99.2%	$95.2M+9.9%	$86.6M+0.8%	$86.0M+19.0%	$72.2M+490.0%	$12.2M0.0%	$12.2M0.0%	$12.2M0.0%	$12.2M0.0%	$12.2M
Total Liabilities	$543.4M+388.1%	$111.3M+29.0%	$86.3M-47.8%	$165.2M-65.3%	$476.4M-27.0%	$652.8M-10.3%	$727.7M+4.0%	$699.9M+177.3%	$252.4M+9.4%	$230.7M+2.0%	$226.2M-3.2%	$233.6M+324.0%	$55.1M-29.2%	$77.8M-25.3%	$104.1M
Current Liabilities	$37.4M+0.9%	$37.1M+121.1%	$16.8M-83.0%	$98.8M+137.2%	$41.7M-58.4%	$100.1M+488.8%	$17.0M-79.3%	$82.2M-65.6%	$238.9M+5.2%	$227.1M+1.9%	$222.8M+878.2%	$22.8M-21.3%	$28.9M-18.3%	$35.4M-18.8%	$43.6M
Non-Current Liabilities	$506.0M+581.7%	$74.2M+6.8%	$69.5M+4.7%	$66.4M-84.7%	$434.8M-21.3%	$552.6M-22.2%	$710.7M+15.1%	$617.6M+4473.1%	$13.5M+274.9%	$3.6M+8.2%	$3.3M-98.4%	$210.8M+705.9%	$26.2M-38.2%	$42.3M-29.9%	$60.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$27.5M	N/A
Total Equity	$1.0B+22.5%	$830.4M+18.5%	$700.9M+17.3%	$597.5M-27.2%	$821.2M+15.7%	$709.5M-7.5%	$767.2M+36.8%	$560.9M+40.3%	$399.8M+17.1%	$341.3M+43.8%	$237.3M+801.6%	$26.3M-47.0%	$49.6M+87.3%	$26.5M+223.6%	$8.2M
Retained Earnings	$608.1M+21.9%	$499.0M-0.8%	$503.0M+11.6%	$450.9M+0.4%	$449.1M+14.6%	$392.0M-2.0%	$400.1M+274.6%	-$229.2M+42.8%	-$400.9M+7.0%	-$431.1M-0.4%	-$429.5M+34.9%	-$659.3M+1.8%	-$671.3M+1.7%	-$682.8M-0.1%	-$682.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$2.2B+130.4%	$1.5B+69.2%	$1.6B+65.7%	$1.5B+54.7%	$948.6M+9.5%	$905.4M-0.9%	$941.8M+19.6%	$954.9M+24.1%
Current Assets	$1.5B+312.8%	$865.4M+179.8%	$832.3M+151.0%	$753.9M+143.7%	$352.9M+13.0%	$309.3M-16.2%	$331.6M+39.6%	$309.4M+21.8%
Cash & Equivalents	$1.0B+1387.7%	$115.1M+139.8%	$174.9M+141.9%	$139.4M+119.1%	$67.7M+273.1%	$48.0M-4.2%	$72.3M+215.0%	$63.6M+230.1%
Short-Term Investments	$351.1M+97.9%	$664.3M+312.9%	$558.6M+203.8%	$525.1M+236.6%	$177.4M-15.1%	$160.9M-38.2%	$183.9M+24.8%	$156.0M-8.9%
Inventory	$10.3M-33.7%	$13.3M-9.2%	$9.1M-35.3%	$11.9M-28.9%	$15.5M-17.0%	$14.6M-31.5%	$14.1M-41.1%	$16.7M-34.1%
Accounts Receivable	$67.0M+62.3%	$53.4M+38.7%	$59.6M+55.3%	$57.6M+67.7%	$41.3M+10.2%	$38.5M+35.4%	$38.4M+16.6%	$34.3M-4.7%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$101.5M0.0%	$101.5M0.0%	$101.5M-3.5%	$101.5M-3.5%	$101.5M-3.5%	$101.5M-3.5%	$105.3M+1.8%	$105.3M+1.4%
Total Liabilities	$1.2B+914.7%	$534.8M+386.6%	$543.4M+388.1%	$526.6M+363.2%	$120.1M+31.7%	$109.9M+2.4%	$111.3M+29.0%	$113.7M+12.2%
Current Liabilities	$46.7M-27.8%	$40.7M-30.7%	$37.4M+0.9%	$30.5M+23.3%	$64.7M+248.7%	$58.7M+229.3%	$37.1M+121.1%	$24.8M+57.5%
Non-Current Liabilities	$1.2B+2017.1%	$494.1M+864.7%	$506.0M+581.7%	$496.1M+457.9%	$55.3M-23.8%	$51.2M-42.8%	$74.2M+6.8%	$88.9M+3.9%
Long-Term Debt	$1.1B	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$967.5M+16.9%	$997.3M+25.4%	$1.0B+22.5%	$950.2M+13.0%	$827.3M+6.7%	$795.6M-1.4%	$830.4M+18.5%	$841.2M+25.9%
Retained Earnings	$583.3M+26.4%	$594.7M+30.3%	$608.1M+21.9%	$578.2M+9.1%	$461.4M-14.1%	$456.5M-22.5%	$499.0M-0.8%	$530.1M+9.3%

LGNYZ Cash Flow Statement

LGNYZ quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$131.7M	$49.4M-49.1%	$97.0M+95.8%	$49.6M-64.0%	$137.8M+74.9%	$78.8M+44.4%	$54.6M+286.1%	-$29.3M-115.1%	$194.1M+119.1%	$88.6M+45.8%	$60.7M+45.5%	$41.7M+102.9%	$20.6M-0.6%	$20.7M+12750.9%	$161K+113.7%	-$1.2M
Depreciation & Amortization	N/A	$33.8M-4.2%	$35.2M-3.5%	$36.5M-29.1%	$51.5M+0.9%	$51.1M+98.8%	$25.7M+39.9%	$18.4M+43.6%	$12.8M+16.7%	$11.0M-3.0%	$11.3M+329.8%	$2.6M-1.1%	$2.7M-0.2%	$2.7M-2.3%	$2.7M-2.3%	$2.8M
Stock-Based Compensation	N/A	$46.8M+14.0%	$41.1M+59.6%	$25.7M-57.3%	$60.3M+55.4%	$38.8M+26.2%	$30.7M+25.3%	$24.5M+17.6%	$20.8M-16.3%	$24.9M+31.9%	$18.9M+51.7%	$12.5M+10.5%	$11.3M+98.9%	$5.7M+39.3%	$4.1M+21.4%	$3.4M
Capital Expenditures	$278K	$452K-75.2%	$1.8M-48.3%	$3.5M-80.4%	$17.9M+104.6%	$8.8M+96.5%	$4.5M+74.6%	$2.6M+187.8%	$887K-58.9%	$2.2M+16.5%	$1.9M+1889.2%	$93K+1450.0%	$6K-98.4%	$377K-36.6%	$595K+662.8%	$78K
Free Cash Flow	$131.4M	$48.9M-48.6%	$95.2M+106.8%	$46.1M-61.6%	$119.9M+71.2%	$70.0M+39.7%	$50.1M+257.2%	-$31.9M-116.5%	$193.2M+123.5%	$86.4M+46.8%	$58.9M+41.4%	$41.6M+102.5%	$20.6M+1.2%	$20.3M+4780.4%	-$434K+65.3%	-$1.3M
Investing Cash Flow	-$144.8M	-$377.3M-162.6%	-$143.7M-1129.8%	-$11.7M-107.1%	$163.6M+436.1%	$30.5M-86.8%	$231.6M-50.4%	$466.9M+210.3%	-$423.3M-434.6%	-$79.2M+41.1%	-$134.4M-19.1%	-$112.9M-5467.9%	-$2.0M+59.2%	-$5.0M-493.8%	$1.3M+105.0%	-$25.1M
Financing Cash Flow	$950.3M	$428.2M+340.8%	$97.1M+262.0%	-$59.9M+78.3%	-$276.0M-100.3%	-$137.8M+55.6%	-$310.5M+36.0%	-$485.2M-247.7%	$328.6M+4467.7%	-$7.5M-50.6%	-$5.0M-159.7%	$8.4M-93.6%	$130.0M+890.0%	-$16.5M-520.3%	$3.9M-86.9%	$30.0M
Share Buybacks	N/A	$15.0M	$0	$0	$0	$0-100.0%	$78.0M-82.8%	$453.0M+268.7%	$122.9M+6149.6%	$2.0M-49.6%	$3.9M+697.8%	$489K-99.3%	$68.0M	$0	$0-100.0%	$55K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$24.0M+52.0%	$48.7M+291.4%	$45.9M+61.3%	$13.1M-64.2%	$15.8M+18.7%	-$25.4M-235.8%	$28.5M+253.0%	$36.5M+377.8%
Depreciation & Amortization	$8.2M-3.6%	$8.2M-6.3%	$8.2M-4.8%	$8.3M-8.1%	$8.5M-3.7%	$8.8M+0.1%	$8.6M-3.2%	$9.0M+4.4%
Stock-Based Compensation	N/A	$10.6M+35.2%	N/A	N/A	N/A	$7.8M+6.8%	N/A	N/A
Capital Expenditures	$26K-87.9%	$228K+6.5%	$9K-98.7%	$15K-97.5%	$214K-47.5%	$214K+103.8%	$712K+70.7%	$596K+22.4%
Free Cash Flow	$24.0M+53.9%	$48.5M+288.9%	$45.9M+65.4%	$13.1M-63.6%	$15.6M+20.8%	-$25.7M-237.8%	$27.8M+263.0%	$35.9M+401.9%
Investing Cash Flow	$321.1M+3110.4%	-$94.3M-2027.8%	-$18.1M+53.1%	-$353.4M-660.0%	-$10.7M+80.5%	$4.9M+229.6%	-$38.6M-275.6%	-$46.5M-138.5%
Financing Cash Flow	$546.4M+3544.1%	-$14.1M-197.7%	$8.3M-59.1%	$409.6M+643.7%	$15.0M+58.0%	-$4.7M-139.0%	$20.4M+283.6%	$55.1M+1584.4%
Share Buybacks	N/A	N/A	$0	$15.0M	N/A	N/A	$0	N/A

Not reported in any period shown, so not listed: Dividends Paid.

LGNYZ Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LGNYZ quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	97.5%+1.3pp	96.2%+1.3pp	94.9%+3.0pp	91.9%+6.1pp	85.8%-2.5pp	88.3%-0.2pp	88.5%+4.9pp	83.7%
Operating Margin	15.3%+28.8pp	-13.5%-22.6pp	9.1%+7.5pp	1.6%-41.4pp	43.0%+20.1pp	22.9%	671.0%	65.1%+16.9pp	48.3%+8.0pp	40.3%+2.3pp	38.0%+7.6pp	30.4%-0.1pp	30.5%+29.9pp	0.6%+3.5pp	-2.9%
Net Margin	46.4%+48.8pp	-2.4%-42.1pp	39.7%+56.7pp	-17.0%-40.7pp	23.7%+25.5pp	-1.8%	523.2%	57.0%+48.1pp	8.9%+10.4pp	-1.5%	319.6%	18.6%-4.7pp	23.3%+25.0pp	-1.7%-34.0pp	32.3%
Return on Equity	12.2%+12.7pp	-0.5%-7.9pp	7.4%+13.0pp	-5.6%-12.5pp	7.0%+7.4pp	-0.4%-82.4pp	82.0%+56.5pp	25.6%+22.4pp	3.1%+3.6pp	-0.5%-97.3pp	96.9%+51.2pp	45.7%+22.7pp	23.0%+25.0pp	-2.0%-120.7pp	118.7%
Return on Assets	8.0%+8.4pp	-0.4%-7.1pp	6.6%+11.0pp	-4.4%-8.8pp	4.4%+4.6pp	-0.2%-42.3pp	42.1%+30.7pp	11.4%+9.5pp	1.9%+2.1pp	-0.3%-46.0pp	45.7%+41.0pp	4.7%-6.3pp	10.9%+11.4pp	-0.5%-8.6pp	8.1%
Current Ratio	22.23+13.3x	8.93-5.2x	14.15+11.5x	2.67-8.5x	11.15+6.2x	5.00-61.1x	66.09+55.5x	10.58+9.6x	0.99+0.3x	0.72-0.2x	0.96-7.2x	8.13+7.3x	0.86+0.2x	0.67-0.1x	0.74
Debt-to-Equity	0.53+0.4x	0.130.0x	0.12-0.2x	0.28-0.3x	0.58-0.3x	0.920.0x	0.95-0.3x	1.25+0.6x	0.630.0x	0.68-0.3x	0.95-7.9x	8.88+7.8x	1.11+0.1x	1.04-11.7x	12.71
Asset Turnover	0.170.0x	0.180.0x	0.17-0.1x	0.26+0.1x	0.19+0.1x	0.120.0x	0.08-0.1x	0.200.0x	0.210.0x	0.180.0x	0.14-0.1x	0.25-0.2x	0.47+0.2x	0.30+0.1x	0.25
FCF Margin	18.2%-38.7pp	57.0%+21.9pp	35.1%-26.0pp	61.1%+32.1pp	29.0%-1.7pp	30.6%+57.2pp	-26.5%-103.3pp	76.8%+15.6pp	61.2%+7.2pp	54.0%-3.9pp	57.9%+26.0pp	31.9%-9.6pp	41.5%+42.9pp	-1.4%+2.8pp	-4.2%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	13.5%-4.2pp	33.6%+113.5pp	23.2%+45.7pp	47.6%+41.5pp	17.7%+63.7pp	-79.9%-89.5pp	-22.5%-10.6pp	6.1%-3.3pp
Net Margin	76.2%+66.0pp	-25.8%+67.8pp	75.1%+147.7pp	101.6%	10.2%	-93.6%	-72.6%-137.3pp	-13.8%+17.4pp
Return on Equity	5.0%+4.4pp	-1.3%+4.0pp	4.4%+8.1pp	12.3%+13.2pp	0.6%+7.3pp	-5.3%-16.0pp	-3.7%-6.3pp	-0.9%+0.7pp
Return on Assets	2.2%+1.7pp	-0.9%+3.8pp	2.9%+6.2pp	7.9%+8.7pp	0.5%+6.5pp	-4.7%-14.1pp	-3.3%-5.6pp	-0.8%+0.6pp
Current Ratio	31.18+25.7x	21.28+16.0x	22.23+13.3x	24.69+12.2x	5.45-11.4x	5.27-15.4x	8.93-5.2x	12.49-3.7x
Debt-to-Equity	1.16+1.0x	0.54+0.4x	0.53+0.4x	0.55+0.4x	0.150.0x	0.140.0x	0.130.0x	0.140.0x
Asset Turnover	0.030.0x	0.030.0x	0.040.0x	0.080.0x	0.050.0x	0.050.0x	0.050.0x	0.050.0x
FCF Margin	37.7%+4.9pp	93.7%+150.3pp	76.9%+12.1pp	11.3%-58.0pp	32.7%+1.6pp	-56.6%-116.7pp	64.8%+37.6pp	69.3%+47.6pp

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Where LIGAND PHARMS GENERAL CVR Ranks

Frequently Asked Questions

What is LIGAND PHARMS GENERAL CVR's annual revenue?

LIGAND PHARMS GENERAL CVR (LGNYZ) reported $268.1M in total revenue for fiscal year 2025. This represents a 60.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is LIGAND PHARMS GENERAL CVR's revenue growing?

LIGAND PHARMS GENERAL CVR (LGNYZ) revenue grew by 60.4% year-over-year, from $167.1M to $268.1M in fiscal year 2025.

Is LIGAND PHARMS GENERAL CVR profitable?

Yes, LIGAND PHARMS GENERAL CVR (LGNYZ) reported a net income of $124.5M in fiscal year 2025, with a net profit margin of 46.4%.

What is LIGAND PHARMS GENERAL CVR's EBITDA?

LIGAND PHARMS GENERAL CVR (LGNYZ) had EBITDA of $74.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is LIGAND PHARMS GENERAL CVR's operating margin?

LIGAND PHARMS GENERAL CVR (LGNYZ) had an operating margin of 15.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is LIGAND PHARMS GENERAL CVR's net profit margin?

LIGAND PHARMS GENERAL CVR (LGNYZ) had a net profit margin of 46.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is LIGAND PHARMS GENERAL CVR's return on equity (ROE)?

LIGAND PHARMS GENERAL CVR (LGNYZ) has a return on equity of 12.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is LIGAND PHARMS GENERAL CVR's free cash flow?

LIGAND PHARMS GENERAL CVR (LGNYZ) generated $48.9M in free cash flow during fiscal year 2025. This represents a -48.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is LIGAND PHARMS GENERAL CVR's operating cash flow?

LIGAND PHARMS GENERAL CVR (LGNYZ) generated $49.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are LIGAND PHARMS GENERAL CVR's total assets?

LIGAND PHARMS GENERAL CVR (LGNYZ) had $1.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are LIGAND PHARMS GENERAL CVR's capital expenditures?

LIGAND PHARMS GENERAL CVR (LGNYZ) invested $452K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does LIGAND PHARMS GENERAL CVR spend on research and development?

LIGAND PHARMS GENERAL CVR (LGNYZ) invested $81.2M in research and development during fiscal year 2025.

Does LIGAND PHARMS GENERAL CVR buy back shares?

Yes, LIGAND PHARMS GENERAL CVR (LGNYZ) spent $15.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does LIGAND PHARMS GENERAL CVR have outstanding?

LIGAND PHARMS GENERAL CVR (LGNYZ) had 20M shares outstanding as of fiscal year 2025.

What is LIGAND PHARMS GENERAL CVR's current ratio?

LIGAND PHARMS GENERAL CVR (LGNYZ) had a current ratio of 22.23 as of fiscal year 2025, which is generally considered healthy.

What is LIGAND PHARMS GENERAL CVR's debt-to-equity ratio?

LIGAND PHARMS GENERAL CVR (LGNYZ) had a debt-to-equity ratio of 0.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is LIGAND PHARMS GENERAL CVR's return on assets (ROA)?

LIGAND PHARMS GENERAL CVR (LGNYZ) had a return on assets of 8.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is LIGAND PHARMS GENERAL CVR's Piotroski F-Score?

LIGAND PHARMS GENERAL CVR (LGNYZ) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are LIGAND PHARMS GENERAL CVR's earnings high quality?

LIGAND PHARMS GENERAL CVR (LGNYZ) has an earnings quality ratio of 0.40x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can LIGAND PHARMS GENERAL CVR cover its interest payments?

LIGAND PHARMS GENERAL CVR (LGNYZ) has an interest coverage ratio of 8.70x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.